Floatz logo

Pyrotinib

ALK-negative Anaplastic Large Cell Lymphoma

BeiGeneSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the ALK-negative Anaplastic Large Cell Lymphoma cohort.

Asset / SponsorPhaseRating
PREDNISONE TABLETS
Shanghai Jiao Tong University School of Medicine
Phase 4BBB
(+)-VINCRISTINE
Shanghai Jiao Tong University School of Medicine
Phase 4BBB
Ifosfamide
Shandong Provincial Hospital
Phase 4BB
ETOPOSIDE
City of Hope Medical Center
Phase 4BB
Theprubicin
Ruijin Hospital
Phase 4BB

View all 10 →

Same molecule, other indications

Pyrotinib is also rated in:

Non Small Cell Lung CancerDormant
BB
Indicative ·
70 / 100
View asset →
breast carcinomaDormant
BB
Indicative ·
70 / 100
View asset →
Small Cell Lung CancerDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →